Robert C. Flanigan - Concepedia

Author

Robert C. Flanigan

Also Known As

Flanigan RC, R C Flanigan, R FLANIGAN, R. C. FLANIGAN, R. C. Flanigan, R. Flanigan, R.C. FLANIGAN, R.C. Flanigan, ROBERT C. FLANIGAN, Robert C Flanigan

350

Publications

12.5K

Citations

H-Index

135

Concepts

All Affiliations

Loyola University Medical Center Loyola University Chicago University of Kentucky Edward Hines, Jr. VA Hospital University of Illinois Chicago

About

Robert C. Flanigan is an author at Loyola University Medical Center specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	53	3.2K
2	Health Sciences	7	7	325
3	Arts	1	1	165
4	Engineering	1	1	26
5	Nursing	1	1	165

Robert C. Flanigan

130

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, New England Journal of Medicine	2001	1.7K
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease William J. Catalona, Alan W. Partin, Kevin M. Slawin, JAMA	1998	1.2K
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis Robert C. Flanigan, G. Mickisch, Richard Sylvester, The Journal of Urology	2004	871
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Maria Mercader, Barbara Bodner, Micheal T. Moser, Proceedings of the National Academy of Sciences	2001	383
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging William J. Catàlona, Paula C. Southwick, Kevin M. Slawin, Urology UrologyCancer DetectionCancer ScreeningMedicineBiostatistics	2000	334
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski, The Lancet UrologySurgical OncologyVersus ObservationGenitourinary CancerMedicine	2008	328
Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves William J. Catàlona, M’Liss A. Hudson, Peter T. Scardino, The Journal of Urology UrologyOncologyGenitourinary CancerCancer DetectionCancer Screening	1994	319
ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: HEMODYNAMIC PROFILES AND THEIR CORRELATION WITH THE RECOVERY OF ERECTILE FUNCTION John P. Mulhall, Ron Slovick, James M. Hotaling, The Journal of Urology	2002	256
5-YEAR OUTCOME OF SURGICAL RESECTION AND WATCHFUL WAITING FOR MEN WITH MODERATELY SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: A DEPARTMENT OF VETERANS AFFAIRS COOPERATIVE STUDY Robert C. Flanigan, Domenic J. Reda, John H. Wasson, The Journal of Urology	1998	249
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination Jerome P. Richie, William J. Catàlona, Frederick R. Ahmann, Urology UrologyGenitourinary CancerCancer DetectionCancer ScreeningMedicine	1993	231

Page 1